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Abstract: The paper addresses the safety of febuxostat and summarizes reports on side effects and
interactions of febuxostat published by the cut-off date (last day of literature search) of 20 March
2018. Publications on side effects and the interactions of febuxostat were considered. Information
concerning the occurrence of side effects and interactions in association with the treatment with
febuxostat was collected and summarized in the review. The incidence of severe side effects was
much less frequent than mild side effects (1.2–3.8% to 20.1–38.7%). The rate and range of febuxostat
side effects are low at doses of up to 120 mg and only increase with a daily dose of over 120 mg.
The publications reveal no age-dependent increase in side effects for febuxostat. In patients with
impaired renal function, no increase in adverse events is described with a dose of up to 120 mg of
febuxostat per day. Patients with impaired liver function had no elevated risk for severe side effects.
A known allopurinol intolerance increases the risk of skin reactions during treatment with febuxostat
by a factor of 3.6. No correlation between treatment with febuxostat and agranulocytosis has been
confirmed. Possible interactions with very few medications (principally azathioprine) are known for
febuxostat. Febuxostat is well tolerated and a modern and safe alternative to allopurinol therapy.
Keywords: febuxostat; side effects; interactions
1. Introduction
Allopurinol (market launch in Germany 1964, [1]) and febuxostat (market launch in Germany
2010, [2]) are two inhibitors of the xanthine oxidase. Febuxostat is, other than allopurinol, a non-purine
xanthine oxidase inhibitor (see Figure 1) [3].
Figure 1. Chemical structures of allopurinol and febuxostat [3].
Spiekermann showed, that the xanthine oxidase is also located in the vessel wall [4].
There is evidence for a connection between the activity of xanthine oxidase and vasodilation as
well as endothelial function [5]. The free oxygen radicals formed during xanthine oxidase play
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an important pathophysiological role in this context [6]. It was demonstrated that—in contrast
to allopurinol—febuxostat has a positive impact on stress parameters and vascular elasticity [7].
The present review addresses the following questions:
1. What is known from scientific publications with regard to side effects and interactions during
treatment with the xanthine oxidase inhibitor febuxostat?
2. Febuxostat’s safety profile in comparison and contrast to allopurinol.
2. Results
2.1. Findings in Original Works and Secondary Analyses
Tables A1 and A2 present the original works and secondary analyses with the respective events
that occurred.
The results of the evaluation of the stated publications are summarized below by content.
The administered daily febuxostat dose in the reviewed papers was between 10 mg and 240 mg.
In the original papers and secondary analyses, at least one side effect (without severe side effects)
occurred in 20.1% and 39.7% of the patients and at least one severe side effect in 1.2% and 3.8%,
respectively. The five most frequently reported side effects were musculoskeletal symptoms (7.7% of
the patients who received febuxostat); upper respiratory tract symptoms (5.4%); changes in liver
function values (4.7%); diarrhea (3.6%); headache (2.8%). Of the patients in the original papers and
secondary analyses, 2.9% and 1.0%, respectively, dropped out of the study prematurely due to side
effects. The most frequent side effect reported in the original papers that resulted in a patient dropping
out of the study prematurely was an increase in liver values (20.9%) [8–12]. Other reasons were
diarrhea (12.0%), rash (1.7%), as well as cardiac symptoms (1.7%). The latter were three patients
with unspecified cardiovascular symptoms [9], one patient with precordial pain [13], one patient
with palpitations and chest pain [14], as well as one patient with acute heart failure [15]. In the
CARES-study from White et al., the incidence of major cardiovascular events was similar in both
groups [16]. “Sudden cardiac death was [ . . . ] occuring in [ . . . ] 2.7% [of the patients] in the febuxostat
group and [ . . . ] 1.8% [of the patients] in the allopurinol group” [16]. The risk of cardiovascular death
was higher under febuxostat therapy compared to allopurinol in patients with gout [16]. The overall
mortality in both groups was similar [16].
2.1.1. Duration of therapy and dosage
An increase in the occurrence of events with the increasing duration of the therapy was shown
for severe side effects (see Figure 2). The share of patients affected increased from 0.6% (up to one
week) to 3.5% (more than one year). The share of patients with at least one side effect (without
severe side effects) was in a range between 4.7% (duration of therapy over one week to one month)
and 53.3% (duration of therapy over six months to one year) during the therapy periods considered.
The share of these patients in the periods considered were the lowest for a duration of therapy over
one week to one month (4.7%) and over one year (26.9%). The share of patients who dropped out of
the study prematurely due to side effects increased from 0.9% (duration of therapy up to 1 week) to
6.4% (duration of therapy of more than one year).
As the dose increased, the share of patients with at least one side effect (without severe side
effects) was 72% at a daily dose of febuxostat of more than 120 mg (see Figure 3). At lower doses,
this share was a maximum of 41.8%. In the dose group of 81 to 120 mg/day compared with the dose
group of 51 to 80 mg/day, an increase in the share of patients with at least one severe side effect due
to febuxostat from 2.6% to 4.8% was observed. The share of patients who dropped out of the study
prematurely increased to a maximum of 9% in the highest dose group (121 and more mg/day).
Pharmaceuticals 2018, 11, 51 3 of 19
Figure 2. Occurrence of adverse events in dependence on therapy duration (n (therapy duration up
to one week) = 332; n (therapy duration over one week to one month) = 6525; n (therapy duration
over one month to six months) = 3170; n (therapy duration over six months to one year) = 1297;
n (therapy duration over one year) = 917; per therapy period differentiation between patients with at
least one side effect (column 1), patients with at least one severe side effect (column 2), patients who
dropped out of the study prematurely (column 3)) [2,8–15,17–52].
Figure 3. Occurrence of adverse events in dependence on febuxostat dosage (n (up to 40 mg/day) = 1803;
n (41 to 80 mg/day) = 2361; n (81 to 120 mg/day) = 673; n (121 and more mg/day) = 200; for each dose
group differentiation between: patients with at least one side effect (column 1), patients with at least one
severe side effect (column 2), patients who dropped out prematurely (column 3); daily dose used in mg/day
for each dose group: up to 40 mg/day: 10, 20, 30, 40; 41 to 80 mg/day: 50, 60, 70, 80; 81 to 120 mg/day:
90, 120; 121 mg/day and more: 160, 180, 240) [8,9,11–13,15,17–27,29,31,33–36,38,41,42,45,48–54].
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A quantification of the interaction between the duration of therapy and the dose was not possible
based on the information provided in the original studies.
2.1.2. Renal Function
The share of patients with impaired renal function, who experienced at least one side effect
(without severe side effects) was a maximum of 14.3% and thus lower than for patients with
normal renal function (27.4%) (see Figure 4). The maximum febuxostat dose for patients with
impairment in renal function was at 80 mg/day, lower than for patients with normal renal function
(maximum 240 mg/day).
2.1.3. Liver Function
The metabolisation of febuxostat in the body largely takes place in the liver [50]. In the study
by Khosravan et al., the subjects were allocated into three groups based on the individual hepatic
function as determined by Child-Pugh [50]. In patients with moderately impaired liver function, the
share of patients with at least one side effect (without severe side effects) was 75% and therefore three
times as high as in the patient group with normal liver function (25%) [50] (see Table 1). The daily dose
of febuxostat in all groups was 80 mg [50]. The most frequently reported side effects (without severe
side effects) were headache, abdominal pain, and diarrhea, as well as a change in the frequency of
micturition [50]. It was not necessary to adjust the febuxostat dose in any of the cases [50]. No severe
side effects occurred in any of the groups [50].
Figure 4. Occurrence of adverse events depending on renal function (n (patients with normal
renal function) = 1812; n (patients with CLcr >= 50 and <80 mL/min) = 11; n (patients with
CLcr <60 mL/min) = 610; n (patients with CLcr >=30 and <50 mL/min) = 35; n (patients with
CLcr <30 mL/min incl. hemodialysis) = 399; per patient group (sorted by renal function,
left starting with the best) differentiation between patients with at least one side effect (column 1),
patients with at least one severe side effect (column 2), patients who dropped out prematurely
(column 3)) [12–14,17–20,22,24–26,29,31,34,35,37,38,41,44–46,48–52,55].
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Table 1. Adverse events in patients depending on liver function (number of patients examined
per group (column 1); liver function of patient group (column 2); patients with at least one side
effect (column 3); patients with at least one severe side effect (column 4); publications reviewed
(column 5); differentiation between side effect and severe side effect in accordance with the publications,
no standard definition).
Number of Patients with
Febuxostat Therapy Liver Function
Number of
Patients with at
Least One Side
Effect (Share in %)
Number of Patients
with at Least One
Severe Side Effect
(Share in %)
Source
12 Normal 3 (25.0) 0
[50]8 Mildly limited 5 (63.0) 0
8 Moderately limited 6 (75.0) 0
2.1.4. Diabetes mellitus type 2
The occurrence of adverse events during treatment with febuxostat in patients with and without
diabetes mellitus type 2 is comparable based on the publications reviewed (see Figure 5) [39,56].
Figure 5. Occurrence of adverse events in patients with and without diabetes mellitus type 2
(n (Study population) = 1462; classification of patients by patients with and without diabetes mellitus
type 2 as well as respective febuxostat dose (40 or 80 mg/day); in each case, illustration of patients
who experienced at least one side effect (column 1), patients who experienced at least one severe side
effect (column 2), patients who dropped out of the study prematurely (column 3)) [56].
In Ito et al. [39], at least one side effect (without severe side effects) occurred among 13.5% of the
diabetes patients treated with febuxostat. Among patients without diabetes mellitus type 2 the share
was 20% [39].
Becker et al. [56] showed that the urate lowering efficiency of febuxostat (reducing the serum
urate level below 6 mg/dL) is dose dependent in both patients with and without renal insufficiency.
Febuxostat at a daily dose of 80 mg was more efficient than 40 mg at any level of renal insufficiency
(see Figure 6). This holds true for both diabetic and non-diabetic patients [56].
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Figure 6. Comparing diabetic and non-diabetic patients and the urate lowering efficiency of febuxostat
(patients with achievement of serum urate level < 6.0 mg/dL in percent) at a daily dose of febuxostat of
40 mg/day respectively 80 mg/day with regard to the renal function level (sUA: serum urate level) [56].
2.1.5. Age Dependency
Studies indicated an increase in adverse events in patients over 65 years of age [21,57]. The share
of patients who experienced at least one side effect (without severe side effects) and one severe side
effect was twice as high in the group of patients over the age of 65 (58.3% and 6.3%) than in the group
of patients under 65 years (29.2% and 2.5%) [57]. The number of comorbidities in the study population
of the patients under 65 years was in part only half as high as in the group of patients over 65 [57].
In the younger group every patient took an average of 3.8 medications versus 7.1 medications in the
older patient group [57].
2.1.6. Pre-existing Allopurinol Intolerance
Based on the reviewed publications, the risk of a skin reaction (exanthem, pruritus) is higher by
a factor of 3.6 under therapy with febuxostat in patients with a pre-existing allopurinol intolerance [28].
2.1.7. Combination of Febuxostat with NSAIDs
Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used to treat acute attacks of
gout. The incidence of side effects was investigated during simultaneous therapy with febuxostat
together with Indometacin or Naproxen (see Table 2) [52].
Table 2. Side effects during therapy with febuxostat and NSAID (applied NSAID (column 1); number
of patients who were administered the NSAID (column 2); patients with at least one side effect during
therapy with febuxostat (column 3), febuxostat together with NSAID (column 4); NSAID (column 5);
publications reviewed (column 6)).
NSAID Number of
Patients Examined
Number of Patients with at Least One Side Effect
(Share in % a Study Population) Source
Febuxostat Febuxostat + NSAID NSAID
Indometacin 27 2 (8.0) 6 (22.0) 7 (27.0)
[52]Naproxen 26 7 (28.0) 9 (35.0) 7 (26.0)
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Based on the publications reviewed regarding the side effect profile, Indometacin and Naproxen
can be prescribed parallel to a therapy with febuxostat to the extent that there is no contraindication
for NSAID therapy in a given case [52].
2.1.8. Combination of Febuxostat with Hydrochlorothiazide
In the therapy of febuxostat together with hydrochlorothiazide, 43% of the patients developed
at least one side effect [12]. This share was 41% when the only treatment given was febuxostat [12].
Severe side effects did not occur [12]. The combined therapy of febuxostat and hydrochlorothiazide was
well tolerated [12]. No dose adjustment is required for the simultaneous administration of febuxostat
and hydrochlorothiazide [12].
2.1.9. Combination of Febuxostat with Uricosuric Drugs
Lesinurad (approved in Europe) and Arhalofenat (not yet approved in Europe) are drugs that
increase the excretion of uric acid in the urine and are used to treat hyperuricemia and gout [58,59].
In 21 patients treated with febuxostat (40 or 80 mg/day) together with Lesinurad (400 to 600 mg/day),
a total of 27 side effects and no severe side effects occurred [58]. During the combined use of febuxostat
(40 and 80 mg/day) and Arhalofenat (600 or 80 mg/day) in 32 patients, 23 patients (72%) experienced
at least one side effect and no severe side effects [59].
2.1.10. Combination of Febuxostat with Azathioprine
Two cases of a pancytopenia or eosinophilia have been published to date in response to a possible
interaction between febuxostat and azathioprine [55,60]. Both authors consider an interaction of these
two medications as the probable source of the symptoms [55,60]. Patients experienced, among other
adverse reactions, nausea and vomiting, watery diarrhea with weight loss, as well as pancytopenia [55];
other manifestations included fever and a case of eosinophilia [60].
2.1.11. Combination of Febuxostat with Theophylline
The coadministration of febuxostat together with theophylline does not affect the
pharmacokinetics of theophylline [24]. Theophylline was well tolerated when administered together
with febuxostat (80 mg/day) without dose adjustment of febuxostat [24].
2.2. Findings of the Case Reports
Research revealed 14 published case reports on side effects of febuxostat. An evaluation of the
cases according to a causality scale like the Naranjo score was not possible as the information given in
the case reports was not detailed enough to do so.
2.2.1. Skin Reactions and DRESS Syndrome
The occurrence of hypersensitive skin reactions in conjunction with febuxostat therapy is described
for 6 patients. The symptoms described range from itching and erythema [61] to “granulomatous
eruption” [62] and “eruptive maculae” [63] to a potentially lethal DRESS syndrome [64–66].
DRESS syndrome is a special variant of hypersensitivity reaction (DRESS: drug reaction with
eosinophilia and systemic symptoms) [64]. It is described in conjunction with febuxostat therapy in
three case reports [64–66]. In two of the three patients reported with DRESS syndrome, an intolerance
for allopurinol had occurred in the past [65,66]; this event had probably also occurred once in the past
with the third patient during allopurinol treatment [64]. Skin reactions occurred in the past during
therapy with allopurinol in a total of five of six patients (83.5%) with hypersensitive skin reactions.
All described patients recovered. No patient died, see [61–66].
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2.2.2. Rhabdomyolysis
Three cases of rhabdomyolysis have been described [67–69]. One of the patients had a history
of a hypersensitive reaction to allopurinol [68]. Two of the patients had impaired renal function
with a eGFR of 45 mL/min [67] and 35 ± 7 mL/min [68]. The authors saw a correlation with the
development of rhabdomyolysis and the co-administration of a statin together with colchicine [67] or
a fibrate [68] parallel to a therapy with febuxostat. In the third case, no conclusions were drawn to the
causality of rhabdomyolysis [69]. There is no indication that febuxostat could be the sole cause for the
occurrence of a dreaded rhabdomyolysis.
2.2.3. Agranulocytosis
In one paper, two cases of agranulocytosis in the context of treatment with febuxostat are
described [70]. Both patients had chronic renal insufficiency [70]. In this context, a correlation
with the therapy with febuxostat was neither proven nor excluded [70].
2.2.4. Glomerulonephritis
Izzedine et al. [71] describe the case of a 63-year-old man who developed acute kidney failure
with nephrotic syndrome after five months of therapy with febuxostat at an unknown dosage [71].
An ANCA-positive Pauci-immune glomerulonephritis was diagnosed, the cause of which the authors
viewed as the therapy with febuxostat [71].
2.2.5. Acute Liver Disease
Bohm et al. [72] described the case of a 34-year-old patient who developed itching, nausea,
abdominal pain, fatigue, and jaundice during febuxostat therapy [72]. The authors suspect the therapy
with febuxostat to be the cause for the development of this acute liver disease [72]. The authors made
no statements regarding an association with febuxostat or any other causal or predisposing factors.
3. Discussion
According to the findings of the present evaluation, febuxostat is well tolerated. There are no major
differences between the risk profile for allopurinol and febuxostat in regard to the occurrence of side
effects [73]. However, the risk of cardiovascular death was higher under febuxostat therapy compared
to allopurinol in patients with gout, whereas the overall mortality was similar [16]. In Seth et al. [74],
it was demonstrated that the probability of side effects occurring was 1.12 times higher with allopurinol
therapy than with febuxostat [74]. Severe side effects occurred 1.11 times more frequently when
allopurinol was administered compared to febuxostat [74]. In another paper, the probability of side
effects due to the administration of febuxostat was only 0.94 times as high compared to allopurinol [75].
An effect of febuxostat on arterial blood pressure as an adverse event was not reported. There
is indication, that febuxostat lowers blood pressure in patients with normal renal function [76].
An influence on adverse events under febuxostat therapy in the context of the use of alcohol was not
reported. With regard to cardiovascular events during febuxostat therapy, further studies need to be
conducted to evaluate the effect of febuxostat on cardiovascular events and death.
In the present review of the literature, it was determined that an increase in the occurrence of
side effects (without severe side effects) with febuxostat is not to be expected until the daily dose
exceeds 120 mg/day. At a dose of 80 and 120 mg of febuxostat per day, the probability of side effects
occurring is comparatively lower (relative risk: 0.90 and 0.93) than for therapy with allopurinol
(100–300 mg/day) [77]. In the paper by Li et al. [77] it was shown that febuxostat has the lowest risk of
side effects compared to allopurinol and other drugs that lower uric acid levels [77].
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3.1. Renal Function
Based on the available publications, for patients with renal function disorders and extending to
those requiring dialysis treatment, therapy is possible at a daily dose of 80 mg of febuxostat without
an increase in the occurrence of adverse events.
Allopurinol and its active metabolite oxypurinol are excreted exclusively renally [29]. They can
accumulate in patients with renal insufficiency [29]. The excretion of febuxostat is only 50% renal [29].
Its plasma levels (pharmacokinetic) in patients with renal insufficiency up to hemodialysis are
stable [29]. In patients with impaired renal function, the allopurinol dose must be reduced [78].
This may result in a decline in the body’s ability to reduce uric acid levels [79]. In addition,
renal insufficiency increases the risk of a hypersensitivity reaction to allopurinol [79]. Consequently,
a consistent dose reduction is recommended depending on creatinine clearance for allopurinol [79].
According to the findings of the present paper, a dose reduction of febuxostat is not required for patients
with impaired renal function or those requiring hemodialysis. Patients with renal insufficiency must
be extremely closely monitored under allopurinol therapy with careful dose adjustments. There are
always cases in which this is not or not sufficiently practicable.
Bove et al. showed that, in patients with renal dysfunction, the safety profile of febuxostat
compared to allopurinol was better regarding relative risk (RR) of adverse events [80]. A study
with kidney transplant patients showed that the use of febuxostat in those patients was safe [81]. Using
febuxostat, close monitoring of patients with renal insufficiency is not required.
Both allopurinol and febuxostat can be considered in CKD patients. Beside the risk profiles of
both drugs in patients with renal insufficiency, cost and availability of intensive monitoring may also
help make the decision of which to choose.
3.2. Liver Function
The present evaluation revealed an increase in the incidence of adverse events with increasing
impairment of liver function. The probability of the occurrence of side effects in patients with
pre-existing impairment of liver function is also higher during therapy with allopurinol [82].
This applies specifically to “generalized [...] hypersensitivity reactions” [82]. In patients with impaired
liver function, a daily dose of 80 mg febuxostat should not be exceeded according to the findings
of the present evaluation. This is consistent with the current product information on febuxostat:
“The recommended dose for patients with mild liver function impairment [ . . . ] is 80 mg” of febuxostat
in the treatment of gout [83].
3.3. Diabetes Mellitus Type 2
Therapy with febuxostat was tolerated equally well by patients with and without type 2 diabetes
mellitus. There was no increase in the incidence of adverse events for patients with or without type 2
diabetes mellitus undergoing therapy with allopurinol [56]. A dose adjustment is required neither for
febuxostat nor for allopurinol.
3.4. Age Dependence
Patients over 65 years of age developed more adverse events compared to the group of patients
under 65 [21,57]. Regarding adverse events, the factors age, morbidity and medication must be
considered together. From the findings of the present paper, there is no need for a general dose
reduction for older patients [21,57]. It is more important that changes in the side effect profile are
monitored for all patients with several secondary disorders and corresponding drug therapy. This is in
particular also true for the therapy with allopurinol. Interactions must be watched for specifically in the
event of combined therapy of allopurinol with “Mercaptopurine, Azathioprine, Mycophenolatmofetil,
cyclosporin, aluminum hydroxide, Theophylline [or] Warfarin” [84]. Patients treated with one of these
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drugs should not undergo therapy designed to lower uric acid levels with allopurinol, but preferably
be treated with febuxostat.
3.5. Pre-Existing Allopurinol Intolerance
Patients with a pre-existing allopurinol intolerance are more likely to develop intolerance reactions
to febuxostat [28]. Patients with allopurinol intolerance require special medical attention. Patients who
exhibit symptoms of a hypersensitivity reaction during therapy with febuxostat should end therapy
immediately [28,61,62,64–66]. Nevertheless, “hypersensitivity to allopurinol is not a contraindication
to febuxostat” [85].
3.6. Combination of Febuxostat with NSAIDs
Combining febuxostat with NSAID does not result in a significant increase in adverse events based
on the present evaluation [52]. This combination is an alternative to the combination of allopurinol
with an NSAID with regard to side effects.
3.7. Combination of Febuxostat with Hydrochlorothiazide
It was shown that the combined therapy with febuxostat and hydrochlorothiazide is well tolerated
without a dose adjustment [12]. In a therapy with allopurinol, a simultaneous therapy with a thiazide
escalates the risk of a hypersensitivity reaction [86]. Based on the publications analyzed, a therapy with
febuxostat to reduce uric acid levels should be introduced for patients treated with hydrochlorothiazide.
No adjustment of the febuxostat dose is necessary.
3.8. Combination of Febuxostat with Uricosuric Drugs
No severe side effects occurred during the combined therapy of febuxostat together with
Lesinurad or Arhalofenat [58,59]. The question of side effects during the co-administration of
Lesinurad and allopurinol is the subject of current research (see [87,88]). Before a final assessment of
the tolerability of febuxostat in combination with Lesinurad or Arhalofenat can be made, the findings
of additional studies must be waited for. Whether the combination of these new uricosuric agents with
one of the available xanthine oxidase inhibitors has advantages for the patient cannot be inferred from
the available literature.
3.9. Combination of Febuxostat with Azathioprine
In two publications [55,60], the authors report pancytopenia and eosinophilia when febuxostat and
azathioprine are administered together which they consider a possible interaction of the two substances.
In the scope of allopurinol therapy, the interaction with azathioprine is a known complication [89].
Severe side effects can occur [90]. To reduce this risk, the allopurinol dose should be reduced when
combined with azathioprine. In addition, within the scope of allopurinol therapy, an increased risk of
bone marrow suppression with a potential agranulocytosis is known through drug interaction with
azathioprine [84]. Consequently, these complications and interactions should also be considered in
febuxostat therapy if corresponding symptoms occur and immediate action taken, that is, the patient
should discontinue taking the drug. Given an existing therapy with azathioprine, a therapy designed
to lower uric acid levels, preferably with febuxostat, should follow.
3.10. Skin Reactions and DRESS Syndrome
In the present analysis, a pre-existing allopurinol intolerance was identified as a risk factor for
the development of an intolerance to febuxostat [61,62,64–66]. Under therapy with allopurinol, up to
0.4% develop a DRESS syndrome [78]. For allopurinol, the greatest risk factor for the occurrence of
a hypersensitivity reaction is an impairment in renal function [78]. Another risk factor is therapy
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of asymptomatic hyperuricemia with allopurinol [78]. A comparable correlation was not described
for febuxostat.
3.11. Rhabdomyolysis
In the paper by Kang et al. [67], the authors hypothesize that the combination of febuxostat,
colchicine, and rosuvastatin may have led to an increase in the plasma levels of one or more of
these drugs and may thus have caused rhabdomyolysis [67]. The risk of developing rhabdomyolysis
following co-administration of colchicine together with a statin is described in various case histories
([91–96]). The simultaneous existence of impaired renal function also raises the risk for rhabdomyolysis
under such combination therapy [91–93,96]. The occurrence of rhabdomyolysis is also described in the
combination of colchicine with fibrates [97]. With regard to patient safety, the symptoms of this side
effect must expressly be watched for, and the patient must be informed if—in addition to febuxostat—a
therapy with a statin, colchicine or a fibrate is intended. In this situation, regular control of the
creatine kinase is to be recommended to be able to catch rhabdomyolysis at an early state. Liu et al.
presented a study with 1332 patients with chronic kidney disease [98]. Forty-one patients developed
a myopathy [98]. “Febuxostat was the culprit agent [ . . . ] in only two patients [ . . . ]” [98]. Further
studies are required to identify the pathophysiologic relation between febuxostat and myopathy.
3.12. Agranulocytosis
In the paper by Kobayashi et al. [70], a correlation with febuxostat therapy could neither be
proven nor excluded. Consequently, it is not possible to definitively state whether febuxostat can cause
agranulocytosis based on the present evaluation. Further studies must be waited for.
3.13. Glomerulonephritis
One case of an ANCA-positive Pauci-immune glomerulonephritis has been published in which
the authors see the cause in therapy with febuxostat [71]. The exact pathophysiological correlation
remains unclarified.
3.14. Acute Liver Disease
A connection between therapy with febuxostat and an underlying acute liver disease is
suspected [72]. The present evaluation has shown that changes in liver values are also one of the side
effects of therapy with febuxostat. This side effect was also the main reason reported for participants
dropping out of the studies prematurely considered in the present review (see studies in Table A1).
The risk of liver damage due to allopurinol is known. In a paper by Singer and Wallace, 72 patients
are cited as having developed a hypersensitivity reaction to allopurinol [99]. Acute liver cell damage
was diagnosed in 37 patients (51.3%) [99].
In the event of corresponding symptoms or changes in laboratory values during therapy with
febuxostat, the prescribing physician should consider the risk of an acute liver disease and closely
monitor therapy control.
4. Materials and Methods
Publications on the side effects and/or interactions of febuxostat were sought in the databases
PubMed and Google scholar (last query on 20 March 2018) as well as in the list of references in located
papers. The search terms used were: febuxostat, adverse effects, adverse events, side effects, interaction,
safety. Original clinical studies, concerned with the treatment of patients with hyperuricemia and gout
with febuxostat, were considered for this review in the case of presenting the number of patients with
adverse events. Forty-eight original papers with 12,323 patients, six secondary analyses in these papers,
as well as 14 case reports of 15 patients were systematically evaluated. The papers were evaluated for
events in conjunction with therapy with febuxostat. These included side effects, severe side effects,
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dropping out of the study prematurely, as well as the death of a study participant. The total number of
side effects that occurred is the sum of mild side effects (referred to as “side effect”) and severe side
effects (referred to as “severe side effect”).
The rating by mild (e.g., headache, diarrhea, nausea) and severe side effect (e.g., hypersensitivity
reactions, major changes in liver values, cardiovascular events) is based on the authors’ rating in their
respective publication. The classification is not based on a standard definition.
Events which were not evaluated as being connected to febuxostat in the respective publications
were not included in this paper’s evaluation. The comparison to allopurinol was made based on
reviews addressing the side effects or interactions of allopurinol.
5. Conclusions
In the interest of preventing hypersensitivity reactions, such as skin reactions or DRESS syndrome,
allopurinol should be carefully used and the therapy should be closely monitored in patients with
impairment of renal or liver function. Febuxostat should be considered for therapy. Higher CV death
rates during febuxostat therapy must also be taken into consideration, although there is no difference
in the overall death rate between patients being treated with febuxostat and those with allopurinol.
No across-the-board dose adjustment for febuxostat is needed for older patients. Existing concomitant
medications must be considered in all age groups. Therapy with allopurinol is contraindicated for
patients with a previously known intolerance for allopurinol. In these cases, febuxostat can still be used
to treat hyperuricemia and gout whereby the risk of intolerances is elevated. This must be watched in
daily clinical practice. In the majority of the published case reports, no correlation of side effects was
shown to therapy with febuxostat.
The present analysis has shown that febuxostat is well tolerated and a modern and safe alternative
to allopurinol therapy. It can be expected that these findings indicate that the agent febuxostat will
continue to become more important in daily clinical practice. This will also have a positive impact on
the quality of care and therapeutic safety of patients with hyperuricemia and gout.
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Appendix A
Table A1. Adverse events in the original works (number of patients examined per study (column 1);
patients with at least one side effect (column 2); patients with at least one severe side effect (column
3); patients who dropped out of the study prematurely (column 4); patients who died (column 5);
publications reviewed (column 6); differentiation between side effect and severe side effect according
to the respective publication, no standard definition).
Number of Patients with
Febuxostat Therapy
Number of
Patients with
at Least One
Side Effect
(Share in %)
Number of Patients
with at Least One
Severe Side Effect
(Share in %)
Number of Patients to
Drop out Prematurely
(Share in %)
Number of
Patients Who
Died (Share in %)
Source
154 60 (38.9) 0 9 (5.8) 0 [26]
15 1 (6.7) 0 0 0 [23]
507 123 (24.3) 32 (6.3) 39 (7.7) 0 [8]
115 14 (12.2) 3 (2.6) 5 (4.3) 0 [49]
32 10 (31.3) 0 0 0 [22]
28 14 (50.0) 0 0 0 [50]
118 57 (48.3) 0 10 (8.5) 0 [51]
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Table A1. Cont.
Number of Patients with
Febuxostat Therapy
Number of
Patients with
at Least One
Side Effect
(Share in %)
Number of Patients
with at Least One
Severe Side Effect
(Share in %)
Number of Patients to
Drop out Prematurely
(Share in %)
Number of
Patients Who
Died (Share in %)
Source
51 9 (17.6) 0 0 0 [52]
92 26 (28.3) 2 (2.2) 3 (3.3) 0 [20]
48 21 (43.8) 0 0 0 [21]
670 462 (69.0) 25 (3.7) 61 (9.1) 0 [9]
116 106 (91.0) 0 13 (11.2) 0 [10]
1513 839 (55.5) 47 (3.1) 110 (7.3) 0 [11]
34 14 (41.2) 0 0 0 [12]
13 1 (7.7) 1 (7.7) 0 0 [32]
6 3 (50.0) 0 0 0 [18]
29 3 (10.3) 0 0 0 [17]
20 8 (40.0) 0 0 0 [45]
122 10 (8.2) 0 0 0 [46]
171 63 (36.8) 0 6 (3.5) 0 [47]
161 39 (24.2) 1 (0.6) 0 0 [48]
69 11 (15.9) 0 1 (1.5) 0 [13]
39 12 (30.8) 0 0 0 [25]
12 2 (16.7) 0 0 0 [24]
33 20 (60.6) 0 2 (6.1) 0 [36]
17 5 (29.4) 0 0 0 [37]
100 1 (1.0) 0 2 (2.0) 0 [27]
344 113 (32.8) 0 21 (6.1) 0 [41]
38 1 (2.6) 0 0 0 [53]
82 10 (12.2) 0 0 0 [33]
70 5 (7.1) 0 4 (5.7) (included in pat.with ≥ 1 side effect) 0 [14]
26 0 0 0 0 [43]
5948 152 (2.6) 15 (0.25) 36 (0.6) 0 [2]
22 0 1 (4.5) 0 0 [42]
151 6 (4.0) 0 0 0 [34]
36 0 0 0 0 [19]
51 5 (9.8) 0 0 0 [29]
45 2 (4.4) 0 0 0 [38]
336 91 (27.1) 1 (0.3) 6 (1.8) 0 [35]
89 33 (37.1) 0 0 0 [30]
101 4 (4.0) 0 0 0 [28]
160 27 (16.9) 0 5 (3.1) 0 [39]
294 18 (6.1) 0 7 (2.4) 0 [44]
83 0 0 6 (7.2) 0 [40]
64 53 (82.8) 13 (20.3) 8 (12.5) 1 (1.6) [15]
54 8 (14.8) 2 (3.7) 0 0 [31]
12,279 2462 (20.1) 143 (1.2) 354 (2.9) 1 (0.008) TOTAL
Appendix B
Table A2. Adverse events in the secondary analyses (number of patients examined per study
(column 1); patients with at least one side effect (column 2); patients with at least one severe side
effect (column 3); patients who dropped out of the study prematurely (column 4); patients who died
(column 5); publications reviewed (column 6); differentiation between side effect and severe side effect
according to the respective publication, no standard definition).
Number of Patients with
Febuxostat Therapy
Number of
Patients with
at Least One
Side Effect
(Share in %)
Number of Patients
with at Least One
Severe Side Effect
(Share in %)
Number of
Patients to
Drop Out
Prematurely
(Share in %)
Number of
Patients Who
Died (Share in %)
Source
1513 ND 49 (3.2) ND 2 (0.7) [57]
116 106 (91.0) 21 (18.0) 13 (11.2) 0 [100]
137 100 (71.9) 9 (6.5) ND 1 (0.7) [101]
243 145 (59.7) 17 (7.0) 34 (14.0) 0 [102]
1399 770 (55.0) 44 (3.2) 0 0 [103]
1462 812 (55.5) 47 (3.2) ND 0 [56]
4870 1933 (39.7) 187 (3.8) 47 (1.0) 3 (0.06) Total
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